Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Tagoor Lab Vildagliptin

    Virtual Booth

    Contact Supplier

    Vildagliptin

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Vildagliptin

    Virtual Booth

    Contact Supplier

    Menu

    Vildagliptin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 475Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 9Equa/EquMet

    02 6Galvus

    03 4Galvus Group

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    Iran Expo
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 391

    2019 Revenue in Millions : 75

    Growth (%) : 421

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    Iran Expo
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 391

    2019 Revenue in Millions : 75

    Growth (%) : 421

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Galvus Group

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Galvus Group

    Switzerland
    arrow
    Iran Expo
    Not Confirmed

    Novartis

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 1,199

    2019 Revenue in Millions : 1,297

    Growth (%) : -8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    Iran Expo
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 322

    2020 Revenue in Millions : 391

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Galvus Group

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Galvus Group

    Switzerland
    arrow
    Iran Expo
    Not Confirmed

    Novartis

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 1,092

    2020 Revenue in Millions : 1,199

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    Iran Expo
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 322

    2020 Revenue in Millions : 391

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    Iran Expo
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 272

    2021 Revenue in Millions : 322

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Galvus Group

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Galvus Group

    Switzerland
    arrow
    Iran Expo
    Not Confirmed

    Novartis

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 859

    2021 Revenue in Millions : 1,092

    Growth (%) : -21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    Iran Expo
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 272

    2021 Revenue in Millions : 322

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Equa/EquMet

    Vildagliptin

    arrow
    Iran Expo
    Not Confirmed

    Brand Name : Equa/EquMet

    U.S.A
    arrow
    Iran Expo
    Not Confirmed

    Dainippon Sumitomo

    Vildagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2023 Revenue in Millions : 210

    2022 Revenue in Millions : 251

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF